https://m2.mtmt.hu/ hun 2026-10-24 07:59 JournalArticle 32092509 VALIDATED true 0 false 2026-10-21T12:41:47.933+0000 2023-10-19T19:39:32.339+0000 2021-07-05T13:32:02.071+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2025-10-19T15:46:57.143+0000 2021-08-13T15:36:43.426+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Kövy, Petra true true /api/journal/10007440 REVIEWED PLOS ONE 1932-6203 true false 10007440 false 10007440 true 1932-6203 Journal FOREIGN 16 6 e0253386 e0253386 18 2021 Funding 2007735 /api/funding/2007735 (BO/00809/18/8) Támogató: MTA false true Funding 2007736 /api/funding/2007736 (ÚNKP-20-3-II-SE-79) false true Funding 2007737 /api/funding/2007737 (ÚNKP-19-4-SE-83) false true Funding 2007738 /api/funding/2007738 (NVKP_ 16-1-2016-0005) Támogató: NKFIH false true Funding 2007739 /api/funding/2007739 (TKP2020-NKA-19) false true Funding 2007740 /api/funding/2007740 (EMMI IV/219-4/2021/EKF) Támogató: EMMI false true true 2021 true true true false true false GOLD 2026-10-21 true https://doi.org/10.1371/journal.pone.0253386 11 0 11 11 0 10 11 10 6 11 11 11 11 11 0 0 11 11 11 11 0 2 2 Folyóiratcikk Journal Article 24 10 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2023 0 5 5 5 5 2024 0 2 2 2 2 2025 0 1 1 1 1 2026 0 2 2 2 2 Q1 A false false false false 2021-07-04T13:32:16.165+0000 Rácz Károly Doktori Iskola (SE); Transzfúziológiai Tanszék (SE / AOK / K) 11 22 2 14 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96743220 /api/authorship/96743220 Kövy, Petra [Kövy, Petra (Klinikai laborató...), szerző] Rácz Károly Doktori Iskola (SE) 1 0.071 true false false Author 10061655 /api/author/10061655 Kövy Petra (Klinikai laboratórium) Kövy Petra true 10061655 true Kövy Petra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743221 /api/authorship/96743221 Őrfi, Zoltán [Őrfi, Zoltán (gyógyszerész, mol...), szerző] 2 0.071428575 false false false Author 10065948 /api/author/10065948 Őrfi Zoltán (gyógyszerész, molekuláris biológia) Őrfi Zoltán true true Őrfi Zoltán true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743222 /api/authorship/96743222 Bors, András [Bors, András (Élettudományok-Bi...), szerző] Transzfúziológiai Tanszék (SE / AOK / K) 3 0.071 false false false Author 10048476 /api/author/10048476 Bors András (Élettudományok-Biológia) Bors András true 10048476 true Bors András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743223 /api/authorship/96743223 Kozma, András [Kozma, András (Biológus), szerző] 4 0.071428575 false false false Author 10081180 /api/author/10081180 Kozma András (Biológus) Kozma András true true Kozma András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743224 /api/authorship/96743224 Gopcsa, László [Gopcsa, László (Belgyógyászat, he...), szerző] 5 0.071428575 false false false Author 10066903 /api/author/10066903 Gopcsa László (Belgyógyászat, hematológia) Gopcsa László true true Gopcsa László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743225 /api/authorship/96743225 Dolgos, János [Dolgos, János (Belgyógyászat, he...), szerző] 6 0.071428575 false false false Author 10066892 /api/author/10066892 Dolgos János (Belgyógyászat, hematológia, onkológia) Dolgos János true true Dolgos János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743226 /api/authorship/96743226 Lovas, Nóra 7 0.071428575 false false false Lovas Nóra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743227 /api/authorship/96743227 Harasztdombi, József [Harasztdombi, József (hematológia), szerző] 8 0.071428575 false false false Author 10089323 /api/author/10089323 Harasztdombi József (hematológia) Harasztdombi József true true Harasztdombi József true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743228 /api/authorship/96743228 Lakatos, Viktor 9 0.071428575 false false false Lakatos Viktor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743229 /api/authorship/96743229 Király, Ágnes 10 0.071428575 false false false Király Ágnes true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743230 /api/authorship/96743230 Mikala, Gábor [Mikala, Gábor (Hematológia), szerző] 11 0.071428575 false false false Author 10048765 /api/author/10048765 Mikala Gábor (Hematológia) Mikala Gábor true 10048765 true Mikala Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743231 /api/authorship/96743231 Vályi-Nagy, István [Vályi-Nagy, István (Hematológia, belg...), szerző] 12 0.071428575 false false false Author 10034838 /api/author/10034838 Vályi-Nagy István (Hematológia, belgyógyászat, onkológia) Vályi-Nagy István true 10034838 true Vályi-Nagy István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743232 /api/authorship/96743232 Reményi, Péter [Reményi, Péter (Belgyógyászat, he...), szerző] 13 0.071428575 false false false Author 10059885 /api/author/10059885 Reményi Péter (Belgyógyászat, hematológia, infektológia) Reményi Péter true 10059885 true Reményi Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96743233 /api/authorship/96743233 Andrikovics, Hajnalka ✉ [Andrikovics, Hajnalka (orvostudomány), szerző] Transzfúziológiai Tanszék (SE / AOK / K) 14 0.071 false true true Author 10036963 /api/author/10036963 Andrikovics Hajnalka (orvostudomány) Andrikovics Hajnalka true 10036963 true Andrikovics Hajnalka true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18983485 /api/publicationidentifier/18983485 DOI: 10.1371/journal.pone.0253386 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1371/journal.pone.0253386 https://doi.org/10.1371/journal.pone.0253386 false true PublicationIdentifier 19087982 /api/publicationidentifier/19087982 WoS: 000671691000032 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000671691000032 https://www.webofscience.com/wos/woscc/full-record/000671691000032 true true PublicationIdentifier 18983486 /api/publicationidentifier/18983486 Scopus: 85108368352 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85108368352 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85108368352 false true PublicationIdentifier 19087983 /api/publicationidentifier/19087983 PubMed: 34153064 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 34153064 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34153064&dopt=Abstract true true MtaRating 10486385 /api/mtarating/10486385 II. Pedagógiai Tudományos Bizottság:A PLOS ONE 1932-6203 RatingType 10023 /api/ratingtype/10023 II. Pedagógiai Tudományos Bizottság PedTB Institute 14107 /api/institute/14107 Pedagógiai Tudományos Bizottság II. FTO PedTB [1901-] 0 false true false Pedagógiai Tudományos Bizottság Pedagógiai Tudományos Bizottság true 14107 true true true A true true MtaRating 519076 /api/mtarating/519076 IX. Szociológiai Tudományos Bizottság:A nemzetközi PLOS ONE 1932-6203 RatingType 10007 /api/ratingtype/10007 IX. Szociológiai Tudományos Bizottság SZTB Institute 14102 /api/institute/14102 Szociológiai Tudományos Bizottság IXGJO SZTB [1901-] 0 false true false Szociológiai Tudományos Bizottság Committee on Sociology true 14102 true true true A nemzetközi true 19076 true MtaRating 11551131 /api/mtarating/11551131 IX. Regionális Tudományok Bizottsága:B nemzetközi PLOS ONE 1932-6203 RatingType 10010 /api/ratingtype/10010 IX. Regionális Tudományok Bizottsága RegTB Institute 14100 /api/institute/14100 Regionális Tudományok Bizottsága IXGJO RTB [1901-] 0 false true false Regionális Tudományok Bizottsága Committee on Regional Studies true 14100 true true true B nemzetközi true true SjrRating 11185000 /api/sjrrating/11185000 sjr:Q1 (2021) Scopus - Multidisciplinary PLOS ONE 1932-6203 1932-6203 16 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1000 /api/classificationexternal/1000 Scopus - Multidisciplinary true 1000 true Q1 DIRECT true true Reference 21601007 /api/reference/21601007 1. H Döhner 2017: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel., Blood, 129, p. 424, DOI: 10.1182/blood-2016-08-733196 1 10.1182/blood-2016-08-733196 false true Reference 21601008 /api/reference/21601008 2. M Jongen-Lavrencic 2018: Molecular Minimal Residual Disease in Acute Myeloid Leukemia., The New England journal of medicine, 378, p. 1189, DOI: 10.1056/NEJMoa1716863 2 10.1056/NEJMoa1716863 false true Reference 21601009 /api/reference/21601009 3. GJ Schuurhuis 2018: Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party., Blood, 131, p. 1275, DOI: 10.1182/blood-2017-09-801498 3 10.1182/blood-2017-09-801498 false true Reference 21601010 /api/reference/21601010 4. H Döhner 2015: Acute Myeloid Leukemia., The New England journal of medicine, 373, p. 1136, DOI: 10.1056/NEJMra1406184 4 10.1056/NEJMra1406184 false true Reference 21601011 /api/reference/21601011 5. B Falini 2020: NPM1-mutated acute myeloid leukemia: from bench to bedside., Blood, 136, p. 1707, DOI: 10.1182/blood.2019004226 5 10.1182/blood.2019004226 false true Reference 21601012 /api/reference/21601012 6. E Papaemmanuil 2016: Genomic Classification and Prognosis in Acute Myeloid Leukemia., The New England journal of medicine, 374, p. 2209, DOI: 10.1056/NEJMoa1516192 6 10.1056/NEJMoa1516192 false true Reference 21601013 /api/reference/21601013 7. ME Figueroa 2010: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation., Cancer cell, 18, p. 553, DOI: 10.1016/j.ccr.2010.11.015 7 10.1016/j.ccr.2010.11.015 false true Reference 21601014 /api/reference/21601014 8. D Grimwade 2016: Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance., Blood, 127, p. 29, DOI: 10.1182/blood-2015-07-604496 8 10.1182/blood-2015-07-604496 false true Reference 21601015 /api/reference/21601015 9. M Koszarska 2013: Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia., Leukemia & lymphoma, 54, p. 1028, DOI: 10.3109/10428194.2012.736981 9 10.3109/10428194.2012.736981 false true Reference 21601016 /api/reference/21601016 10. P Kövy 2019: Új terápiás célpont akut myeloid leukémiában: izocitrát dehidrogenáz 1 és 2 mutációk., Hematológia Transzfuziológia, 152, p. 142 10 false true Reference 21601017 /api/reference/21601017 11. C Thiede 2006: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)., Blood, 107, p. 4011, DOI: 10.1182/blood-2005-08-3167 11 10.1182/blood-2005-08-3167 false true Reference 21601018 /api/reference/21601018 12. WC Chou 2007: Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations., Leukemia, 21, p. 998, DOI: 10.1038/sj.leu.2404637 12 10.1038/sj.leu.2404637 false true Reference 21601019 /api/reference/21601019 13. P Gorello 2006: Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations., Leukemia, 20, p. 1103, DOI: 10.1038/sj.leu.2404149 13 10.1038/sj.leu.2404149 false true Reference 21601020 /api/reference/21601020 14. N Mencia-Trinchant 2017: Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations., The Journal of molecular diagnostics: JMD, 19, p. 537, DOI: 10.1016/j.jmoldx.2017.03.005 14 10.1016/j.jmoldx.2017.03.005 false true Reference 21601021 /api/reference/21601021 15. M Waterhouse 2019: Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation., Clin Chem Lab Med, 57, p. 641, DOI: 10.1515/cclm-2018-0827 15 10.1515/cclm-2018-0827 false true Reference 21601022 /api/reference/21601022 16. M Alizadeh 2002: Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction., Blood, 99, p. 4618, DOI: 10.1182/blood.V99.12.4618 16 10.1182/blood.V99.12.4618 false true Reference 21601023 /api/reference/21601023 17. E Beillard 2003: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ’real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program., Leukemia, 17, p. 2474, DOI: 10.1038/sj.leu.2403136 17 10.1038/sj.leu.2403136 false true Reference 21601024 /api/reference/21601024 18. NC Cross 2015: Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia., Leukemia, 29, p. 999, DOI: 10.1038/leu.2015.29 18 10.1038/leu.2015.29 false true Reference 21601025 /api/reference/21601025 19. Y Ferret 2018: Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group., Haematologica, 103, p. 822, DOI: 10.3324/haematol.2017.183525 19 10.3324/haematol.2017.183525 false true Reference 21601026 /api/reference/21601026 20. E Topic 2015: How to assess the quality of your analytical method?., Clin Chem Lab Med, 53, p. 1707, DOI: 10.1515/cclm-2015-0869 20 10.1515/cclm-2015-0869 false true Reference 21601027 /api/reference/21601027 21. R Dillon 2020: Molecular MRD status and outcome after transplantation in NPM1-mutated AML., Blood, 135, p. 680, DOI: 10.1182/blood.2019002959 21 10.1182/blood.2019002959 false true Reference 21601028 /api/reference/21601028 22. G Genovese 2014: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence., The New England journal of medicine, 371, p. 2477, DOI: 10.1056/NEJMoa1409405 22 10.1056/NEJMoa1409405 false true Reference 21601029 /api/reference/21601029 23. S Jaiswal 2014: Age-related clonal hematopoiesis associated with adverse outcomes., The New England journal of medicine, 371, p. 2488, DOI: 10.1056/NEJMoa1408617 23 10.1056/NEJMoa1408617 false true Reference 21601030 /api/reference/21601030 24. M Xie 2014: Age-related mutations associated with clonal hematopoietic expansion and malignancies., Nat Med, 20, p. 1472, DOI: 10.1038/nm.3733 24 10.1038/nm.3733 false true Reference 21601031 /api/reference/21601031 25. S Abelson 2018: Prediction of acute myeloid leukaemia risk in healthy individuals., Nature, 559, p. 400, DOI: 10.1038/s41586-018-0317-6 25 10.1038/s41586-018-0317-6 false true Reference 21601032 /api/reference/21601032 26. P Desai 2018: Somatic mutations precede acute myeloid leukemia years before diagnosis., Nat Med, 24, p. 1015, DOI: 10.1038/s41591-018-0081-z 26 10.1038/s41591-018-0081-z false true Reference 21601033 /api/reference/21601033 27. F Forghieri 2020: NPM1-Mutated Myeloid Neoplasms with &lt;20% Blasts: A Really Distinct Clinico-Pathologic Entity?., Int J Mol Sci, 21, DOI: 10.3390/ijms21238975 27 10.3390/ijms21238975 false true Reference 21601034 /api/reference/21601034 28. MR Corces-Zimmerman 2014: Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission., Proc Natl Acad Sci U S A, 111, p. 2548, DOI: 10.1073/pnas.1324297111 28 10.1073/pnas.1324297111 false true Reference 21601035 /api/reference/21601035 29. LI Shlush 2014: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia., Nature, 506, p. 328, DOI: 10.1038/nature13038 29 10.1038/nature13038 false true Reference 21601036 /api/reference/21601036 30. WC Chou 2006: Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution., Cancer Res, 66, p. 3310, DOI: 10.1158/0008-5472.CAN-05-4316 30 10.1158/0008-5472.CAN-05-4316 false true Reference 21601037 /api/reference/21601037 31. S Cocciardi 2019: Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation., Nat Commun, 10, p. 2031, DOI: 10.1038/s41467-019-09745-2 31 10.1038/s41467-019-09745-2 false true Reference 21601038 /api/reference/21601038 32. A Höllein 2018: NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse., Blood advances, 2, p. 3118, DOI: 10.1182/bloodadvances.2018023432 32 10.1182/bloodadvances.2018023432 false true Reference 21601039 /api/reference/21601039 33. P Jain 2014: Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse., Leukemia & lymphoma, 55, p. 1337, DOI: 10.3109/10428194.2013.840776 33 10.3109/10428194.2013.840776 false true Reference 21601040 /api/reference/21601040 34. S Kapp-Schwoerer 2020: Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09–09 trial., Blood, 136, p. 3041, DOI: 10.1182/blood.2020005998 34 10.1182/blood.2020005998 false true Reference 21601041 /api/reference/21601041 35. J Krönke 2013: Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia., Blood, 122, p. 100, DOI: 10.1182/blood-2013-01-479188 35 10.1182/blood-2013-01-479188 false true Reference 21601042 /api/reference/21601042 36. G Meloni 2009: Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability., Haematologica, 94, p. 298, DOI: 10.3324/haematol.000059 36 10.3324/haematol.000059 false true Reference 21601043 /api/reference/21601043 37. C Papadaki 2009: Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor., Br J Haematol, 144, p. 517, DOI: 10.1111/j.1365-2141.2008.07488.x 37 10.1111/j.1365-2141.2008.07488.x false true Reference 21601044 /api/reference/21601044 38. S Schnittger 2009: Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML., Blood, 114, p. 2220, DOI: 10.1182/blood-2009-03-213389 38 10.1182/blood-2009-03-213389 false true Reference 21601045 /api/reference/21601045 39. T Suzuki 2005: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia., Blood, 106, p. 2854, DOI: 10.1182/blood-2005-04-1733 39 10.1182/blood-2005-04-1733 false true Reference 21601046 /api/reference/21601046 40. CC Lin 2014: IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution., Am J Hematol, 89, p. 137, DOI: 10.1002/ajh.23596 40 10.1002/ajh.23596 false true Reference 21601047 /api/reference/21601047 41. BC Medeiros 2017: Isocitrate dehydrogenase mutations in myeloid malignancies., Leukemia, 31, p. 272, DOI: 10.1038/leu.2016.275 41 10.1038/leu.2016.275 false true Reference 21601048 /api/reference/21601048 42. A Tefferi 2012: IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F., Leukemia, 26, p. 475, DOI: 10.1038/leu.2011.253 42 10.1038/leu.2011.253 false true Reference 21601049 /api/reference/21601049 43. A Tefferi 2010: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis., Leukemia, 24, p. 1302, DOI: 10.1038/leu.2010.113 43 10.1038/leu.2010.113 false true Reference 21601050 /api/reference/21601050 44. H Debarri 2015: IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association., Oncotarget, 6, p. 42345, DOI: 10.18632/oncotarget.5645 44 10.18632/oncotarget.5645 false true Reference 21601051 /api/reference/21601051 45. CY Ok 2019: Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia., Haematologica, 104, p. 305, DOI: 10.3324/haematol.2018.191148 45 10.3324/haematol.2018.191148 false true Reference 21601052 /api/reference/21601052 46. DH Wiseman 2016: Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia., Leukemia, 30, p. 1946, DOI: 10.1038/leu.2016.93 46 10.1038/leu.2016.93 false true Reference 21601053 /api/reference/21601053 47. VI Gaidzik 2018: DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia., Leukemia, 32, p. 30, DOI: 10.1038/leu.2017.200 47 10.1038/leu.2017.200 false true Reference 21601054 /api/reference/21601054 48. GG Pløen 2014: Persistence of DNMT3A mutations at long-term remission in adult patients with AML., Br J Haematol, 167, p. 478, DOI: 10.1111/bjh.13062 48 10.1111/bjh.13062 false true Reference 21601055 /api/reference/21601055 49. Y Sun 2016: Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission., Leuk Res, 49, p. 102, DOI: 10.1016/j.leukres.2016.09.001 49 10.1016/j.leukres.2016.09.001 false true Reference 21601056 /api/reference/21601056 50. A Tuval 2019: Evolutionary trajectory of leukemic clones and its clinical implications., Haematologica, 104, p. 872, DOI: 10.3324/haematol.2018.195289 50 10.3324/haematol.2018.195289 false true Reference 21601057 /api/reference/21601057 51. NJ Short 2020: Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis., JAMA Oncol, 6, p. 1890, DOI: 10.1001/jamaoncol.2020.4600 51 10.1001/jamaoncol.2020.4600 false true Reference 21601058 /api/reference/21601058 52. HJ Chung 2020: Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay., Ann Lab Med, 40, p. 72, DOI: 10.3343/alm.2020.40.1.72 52 10.3343/alm.2020.40.1.72 false true Reference 21601059 /api/reference/21601059 53. D Link-Lenczowska 2018: A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs., Ann Hematol, 97, p. 2299, DOI: 10.1007/s00277-018-3451-1 53 10.1007/s00277-018-3451-1 false true Reference 21601060 /api/reference/21601060 54. J Maier 2019: Optimized Digital Droplet PCR for BCR-ABL. The Journal of molecular diagnostics., JMD, 21, p. 27 54 false true Reference 21601061 /api/reference/21601061 55. WJ Wang 2018: Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression., Eur J Haematol, 101, p. 291, DOI: 10.1111/ejh.13084 55 10.1111/ejh.13084 false true Reference 21601062 /api/reference/21601062 56. M Waterhouse 2016: Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR., Ann Hematol, 95, p. 739, DOI: 10.1007/s00277-016-2623-0 56 10.1007/s00277-016-2623-0 false true Reference 21601063 /api/reference/21601063 57. A Ivey 2016: Assessment of Minimal Residual Disease in Standard-Risk AML., The New England journal of medicine, 374, p. 422, DOI: 10.1056/NEJMoa1507471 57 10.1056/NEJMoa1507471 false true Reference 21601064 /api/reference/21601064 58. M Balsat 2017: Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group., Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 35, p. 185, DOI: 10.1200/JCO.2016.67.1875 58 10.1200/JCO.2016.67.1875 false true Reference 21601065 /api/reference/21601065 59. J Krönke 2011: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group., Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29, p. 2709, DOI: 10.1200/JCO.2011.35.0371 59 10.1200/JCO.2011.35.0371 false true Reference 21601066 /api/reference/21601066 60. N Shayegi 2013: The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML., Blood, 122, p. 83, DOI: 10.1182/blood-2012-10-461749 60 10.1182/blood-2012-10-461749 false true Reference 21601067 /api/reference/21601067 61. T Stahl 2010: Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis., Leukemia & lymphoma, 51, p. 1837, DOI: 10.3109/10428194.2010.508822 61 10.3109/10428194.2010.508822 false true Reference 21601068 /api/reference/21601068 62. M Hubmann 2014: Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse., Haematologica, 99, p. 1317, DOI: 10.3324/haematol.2014.104133 62 10.3324/haematol.2014.104133 false true Reference 21601069 /api/reference/21601069 63. HB Ommen 2010: Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias., Blood, 115, p. 198, DOI: 10.1182/blood-2009-04-212530 63 10.1182/blood-2009-04-212530 false true Reference 21601070 /api/reference/21601070 64. AK Eisfeld 2020: Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged &lt;60 years., Leukemia, 34, p. 3215, DOI: 10.1038/s41375-020-0872-3 64 10.1038/s41375-020-0872-3 false true Reference 21601071 /api/reference/21601071 65. RF Schlenk 2017: Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia., Leukemia, 31, p. 1217, DOI: 10.1038/leu.2017.22 65 10.1038/leu.2017.22 false true Reference 21601072 /api/reference/21601072 66. F Lussana 2019: Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia., Cancers (Basel)., 11, DOI: 10.3390/cancers11101455 66 10.3390/cancers11101455 false true Reference 21601073 /api/reference/21601073 67. A Bataller 2020: Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease., Br J Haematol, 191, p. 52, DOI: 10.1111/bjh.16857 67 10.1111/bjh.16857 false true Reference 21601074 /api/reference/21601074 68. U Platzbecker 2018: Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial., The Lancet Oncology, 19, p. 1668, DOI: 10.1016/S1470-2045(18)30580-1 68 10.1016/S1470-2045(18)30580-1 false true Reference 21601075 /api/reference/21601075 69. M Bill 2018: Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients., Ann Hematol, 97, p. 1757, DOI: 10.1007/s00277-018-3373-y 69 10.1007/s00277-018-3373-y false true Reference 21601076 /api/reference/21601076 70. M Karas 2016: Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission., Anticancer Res, 36, p. 5487, DOI: 10.21873/anticanres.11130 70 10.21873/anticanres.11130 false true Reference 21601077 /api/reference/21601077 71. S Kayser 2016: Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia., Blood Cancer J, 6, p. e449, DOI: 10.1038/bcj.2016.46 71 10.1038/bcj.2016.46 false true Reference 21601078 /api/reference/21601078 72. CS Hourigan 2020: Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease., Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 38, p. 1273, DOI: 10.1200/JCO.19.03011 72 10.1200/JCO.19.03011 false true Reference 21601079 /api/reference/21601079 73. A Burchert 2020: Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)., Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 38, p. 2993, DOI: 10.1200/JCO.19.03345 73 10.1200/JCO.19.03345 false true Reference 21601080 /api/reference/21601080 74. JM Klco 2015: Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia., Jama, 314, p. 811, DOI: 10.1001/jama.2015.9643 74 10.1001/jama.2015.9643 false true Reference 21601081 /api/reference/21601081 75. RC Lindsley 2015: Acute myeloid leukemia ontogeny is defined by distinct somatic mutations., Blood, 125, p. 1367, DOI: 10.1182/blood-2014-11-610543 75 10.1182/blood-2014-11-610543 false true Reference 21601082 /api/reference/21601082 76. EM Stein 2020: Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study., Blood 76 false true /api/publication/32092509 Kövy Petra et al. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. (2021) PLOS ONE 1932-6203 16 6<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10061655"><a href="/gui2/?type=authors&mode=browse&sel=10061655" target="_blank">Kövy Petra (<span class="authorship-author-name">Kövy Petra</span> <span class="authorAux-mtmt"> Klinikai laboratórium</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/Rácz Károly Doktori Iskola</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10065948"><a href="/gui2/?type=authors&mode=browse&sel=10065948" target="_blank">Őrfi Zoltán (<span class="authorship-author-name">Őrfi Zoltán</span> <span class="authorAux-mtmt"> gyógyszerész, molekuláris biológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048476"><a href="/gui2/?type=authors&mode=browse&sel=10048476" target="_blank">Bors András (<span class="authorship-author-name">Bors András</span> <span class="authorAux-mtmt"> Élettudományok-Biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Transzfúziológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10081180"><a href="/gui2/?type=authors&mode=browse&sel=10081180" target="_blank">Kozma András (<span class="authorship-author-name">Kozma András</span> <span class="authorAux-mtmt"> Biológus</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10066903"><a href="/gui2/?type=authors&mode=browse&sel=10066903" target="_blank">Gopcsa László (<span class="authorship-author-name">Gopcsa László</span> <span class="authorAux-mtmt"> Belgyógyászat, hematológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10066892"><a href="/gui2/?type=authors&mode=browse&sel=10066892" target="_blank">Dolgos János (<span class="authorship-author-name">Dolgos János</span> <span class="authorAux-mtmt"> Belgyógyászat, hematológia, onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Lovas Nóra </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10089323"><a href="/gui2/?type=authors&mode=browse&sel=10089323" target="_blank">Harasztdombi József (<span class="authorship-author-name">Harasztdombi József</span> <span class="authorAux-mtmt"> hematológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Lakatos Viktor </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Király Ágnes </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048765"><a href="/gui2/?type=authors&mode=browse&sel=10048765" target="_blank">Mikala Gábor (<span class="authorship-author-name">Mikala Gábor</span> <span class="authorAux-mtmt"> Hematológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10034838"><a href="/gui2/?type=authors&mode=browse&sel=10034838" target="_blank">Vályi-Nagy István (<span class="authorship-author-name">Vályi-Nagy István</span> <span class="authorAux-mtmt"> Hematológia, belgyógyászat, onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10059885"><a href="/gui2/?type=authors&mode=browse&sel=10059885" target="_blank">Reményi Péter (<span class="authorship-author-name">Reményi Péter</span> <span class="authorAux-mtmt"> Belgyógyászat, hematológia, infektológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10036963"><a href="/gui2/?type=authors&mode=browse&sel=10036963" target="_blank">Andrikovics Hajnalka ✉ (<span class="authorship-author-name">Andrikovics Hajnalka</span> <span class="authorAux-mtmt"> orvostudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Transzfúziológiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32092509" target="_blank">Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia</a></div> <div> <span class="journal-title">PLOS ONE</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/1932-6203">1932-6203</a>)</span>: <span class="journal-volume">16</span> <span class="journal-issue">6</span> <span class="page"> Paper e0253386. 18 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1371/journal.pone.0253386" target="_blank" href="https://doi.org/10.1371/journal.pone.0253386"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000671691000032" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000671691000032"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85108368352" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85108368352"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="34153064" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34153064&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Multidisciplinary&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Pedagógiai Tudományos Bizottság II. FTO PedTB [1901-]&nbsp;&nbsp;&nbsp;A</div> <div class="journal-subject">Szociológiai Tudományos Bizottság IXGJO SZTB [1901-]&nbsp;&nbsp;&nbsp;A nemzetközi</div> <div class="journal-subject">Regionális Tudományok Bizottsága IXGJO RTB [1901-]&nbsp;&nbsp;&nbsp;B nemzetközi</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 11</span> | Független: 11 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 10 | Scopus jelölt:&nbsp;6 | WoS/Scopus jelölt:&nbsp;11 | DOI jelölt:&nbsp;11 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32092509&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32092509</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (BO/00809/18/8) Támogató: MTA, (ÚNKP-20-3-II-SE-79), (ÚNKP-19-4-SE-83), (NVKP_ 16-1-2016-0005) Támogató: NKFIH, (TKP2020-NKA-19), (EMMI IV/219-4/2021/EKF) Támogató: EMMI </div> <div class="lastModified">Utolsó módosítás: 2023.10.19. 21:39 Harasztdombi József (hematológia) </div> </div></div>